MRG 201

Drug Profile

MRG 201

Alternative Names: miR-29 replacement; MRG-201

Latest Information Update: 21 Jul 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator University of Texas Southwestern Medical Center
  • Developer miRagen Therapeutics; Yale University
  • Class Antifibrotics; MicroRNAs; Skin disorder therapies
  • Mechanism of Action Collagen inhibitors; RNA inhibitors; RNA interference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Fibrosis
  • Preclinical Pulmonary fibrosis

Most Recent Events

  • 11 Aug 2017 miRagen Therapeutics plans a phase IIa trial for Fibrosis in patients with a predisposition for keloid formation in 2018
  • 27 Apr 2017 Interim pharmacodynamics, pharmacokinetics data from a phase I trial in volunteers released by miRagen Therapeutics
  • 01 Apr 2017 miRagen Therapeutics completes a phase I trial in Fibrosis (In voluteers) in Canada (NCT02603224)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top